Navigation Links
Bioness Announces NESS H200 and L300 Systems to Be Available at 88 HealthSouth Hospitals Nationwide
Date:7/30/2008

Bioness Inc., an innovative provider of advanced neuromodulation products designed to accelerate recovery from central nervous system disorders, announced today that HealthSouth Corporation, the nation’s largest provider of inpatient rehabilitative healthcare services, will expand the availability of the NESS H200 Hand Rehabilitation System and the NESS L300™ Foot Drop System to 88 rehabilitation hospitals nationwide.

VALENCIA, Calif. (Business Wire EON) July 30, 2008 -- "HealthSouth is committed to using technology effectively for our patients, so we've developed a rigorous process for evaluating and selecting new therapeutic devices," said Dr. Dexanne Clohan, HealthSouth Chief Medical Officer."We look for innovations that would be well accepted by patients and therapists and offer opportunities for improved clinical outcomes."

HealthSouth's Bioness pilot program initially involved 27 hospitals. It will expand its NESS H200 program to 37 hospitals and its NESS L300 program to 54 hospitals. The roll-out into these additional facilities is scheduled for completion by September 2008.

"We are excited about HealthSouth's decision to expand their Bioness programs and allow many more individuals access to our advanced technologies nationwide," said Yitzhak Zilberman, President & CEO of Bioness Inc. "We are proud of this technology and are gratified by HealthSouth's favorable assessment."

Bioness' devices are designed to help patients living with limitations caused by stroke, multiple sclerosis, spinal cord injury, traumatic brain injury and other central nervous system disorders. The NESS H200 Hand Rehabilitation System is designed for patients who have difficulties using their weak or paralyzed arm and hand to perform common tasks that require grasp and release, especially two-handed activities such as pushing a cart
'/>"/>

Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
3. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
4. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
5. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
6. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
11. CNS Response Announces Fiscal Third Quarter 2007 Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...eMarbleEnergyCorp.announcedtodaythatthecompanyandt...lyawarded$2millionbyWashingtonState,sCommunityEcon...nershiptoconstructthestate,sfirstspecialtybiochemi...tmentwillsignificantlyspeedthedevelopmentofourbior...dBlueMarbleEnergyCEOKellyOgilvie."Wearegratefultot...
(Date:11/24/2009)...etforpatientswithadvanced-stage,orrecurrentendomet...rstCall/-AEternaZentarisInc.(NASDAQ: AEZS ;TSX:AEZ...usedonendocrinetherapyandoncology,todayannouncedpo...ytotoxicpeptideconjugate,AEZS-108(formerlyAN-152),....Inapersonalizedhealthcareapproach,thestudyselecte...
(Date:11/24/2009)...rstCall/--Shireplc(LSE:SHP,NASDAQ: SHPGY ),theglo...edthatithassubmittedaMAAtotheEuropeanMedicinesAgen...enttherapyindevelopment,forthetreatmentofType1Gauc...elaglucerasealfathathasbeensubmitted,withprevious,...donaglobalsupplyshortageofthecurrentlyapprovedandm...
(Date:11/24/2009)...swire-FirstCall/--GenomicHealth,Inc.(Nasdaq: GHDX ...tiveChairman,willpresentatthe21stAnnualPiperJaffra...er1,2009at10:00a.m.ET. ,, Toaccesstheliveandsub...InvestorRelationssectionofGenomicHealth,swebsiteat...othewebsiteatleast15minutespriortothebeginningofth...
Breaking Biology Technology:Blue Marble Energy, OPDA Awarded $2M by WA's Community Economic Revitalization Board 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3Genomic Health to Present at Piper Jaffray Health Care Conference 2
...: SHP,NASDAQ: SHPGY ), the global specialty biop...ion agreement with GlaxoSmithKline plc (NYSE: GS...apsules CII with the aim of,improving recognition ...greement covers the United States and will more th...ales effort for VYVANSE by adding over 600 sales,r...
...eted product, a new vaccine against Japanese Encep... - Commercial product launch in the U.S. planned f...E: ICLL) today announced that the U.S. Food and Dr...vaccine for the prevention of Japanese Encephaliti...vaccine - the only such product currently manufact...
...nsulting US, a division of London-based Double Hel...ent of Ann Stuchiner to the position of Vice Presi... highly experienced strategic pricing, reimburseme...perience across the healthcare industry, which pro...n the pharmaceutical, biotechnology and medical de...
Other Biology Technology:Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD 2Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD 3Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD 4Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD 5Shire and GlaxoSmithKline Enter Agreement to Co-promote VYVANSE(R) (lisdexamfetamine dimesylate) CII for the Treatment of Adults With ADHD 6Intercell Announces FDA Approval of IXIARO(R), a Novel Vaccine to Prevent Japanese Encephalitis 2Intercell Announces FDA Approval of IXIARO(R), a Novel Vaccine to Prevent Japanese Encephalitis 3Intercell Announces FDA Approval of IXIARO(R), a Novel Vaccine to Prevent Japanese Encephalitis 4Double Helix Appoints Ann Stuchiner Vice President of US Consulting Division 2
(Date:11/24/2009)... NEW YORK (November 24, 2009) -- The Wildlife Con...evealing that the last remaining population of Sib... to the rising tide of poaching and habitat loss. ...rm Russian officials of what needs to be done to p...t cat. , The report was released by...
(Date:11/24/2009)... (November 24, 2009) New research on bacterial co...tems reveals predictable temporal patterns, sugges...s markers for monitoring climate change in the pol... Proceedings of the National Academy of Sciences ... the six rivers shifted synchronously over time, c...
(Date:11/23/2009)...C. The community-associated strain of the deadly ...nt to most common antibioticsposes a far greater h...ts way into hospitals, according to a study in the... , The new threat is easily picked up in fitnes...s increased the overall burden of MRSA within hosp...
Breaking Biology News(10 mins):Report shows dramatic decline in Siberian tigers 2Researchers establish common seasonal pattern among bacterial communities in Arctic rivers 2New study finds MRSA on the rise in hospital outpatients 2Nurses AFL CIO Unions to Host Michael Moore and Special Screening of New Film at AFL CIO Convention 56663 1Nurses AFL CIO Unions to Host Michael Moore and Special Screening of New Film at AFL CIO Convention 56663 2GENova appoints Director of Asian business development 56661 1GENova appoints Director of Asian business development 56661 2Vita Tech International Inc Donates One Ton of Vitamins To Polio Treatment Centers in Guinea West Africa 13950 1
...ns School of Medicine and their colleagues have fo...ptor in addition to their own can acquire new colo... rapidly to new sensory information than anticipat...lso suggests that when the first ancestral primate...0 million years ago, it probably experienced immed...
...School of Medicine & Dentistry at The Universi...Edinburgh, have discovered a way to kill the cysti...se investigators, under the leadership of Dr. Migu...ogy, have had their research published in the May ...ted in Nature Reviews/Microbiology. , B. cenocepa...
...pment of new neurons in specific brain regions aff...n, new research shows. How these new neurons stor...how they can affect learning and memory in adults...., of the Salk Institute, found that experience enh...called the dentate gyrus, and that more of these n...
Other Biology News:Making mice with enhanced color vision 2Making mice with enhanced color vision 3Key found to kill cystic fibrosis superbug 2Experience affects new neuron survival in adult brain; study sheds light on learning, memory 2
RNA 6000 Nano Chip Kit from Agilent Technologies
Mouse Anti-Human ALPK3 Monoclonal Antibody, Unconjugated, Clone 4G4 from Abnova Corporation
...Lines ,High Quality, Functionally-Validated, Ion C...or having a critical role in nerve and muscle func... CNS and the heart. Drugs that modulate ion channe...ch as neuropathic pain, cardiac arrhythmia, hypert...
Mouse Anti-Human CD320 Polyclonal Antibody, Unconjugated from Abnova Corporation
Biology Products: